# Genprex, Inc. Common Stock (GNPX)

> Genprex, Inc. Common Stock (GNPX) trades at $2.08 (-5.88%) as of 7:13:33 PM EST on Nov 13, 2026, -9.17% over the past month. Market cap is $1.7M, with 1.0 days to cover in short interest.

Canonical: https://massive.com/quote/gnpx
Data as of: 2026-11-14T00:13:33.297Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.08** -0.13 (-5.88%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$2.15** +0.07 (+3.37%)
As of 7:13:33 PM EST on Nov 13, 2026 · After hours

## Stock performance

How Genprex, Inc. Common Stock (GNPX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -5.88% |
| 1W | +0.48% |
| 1M | -9.17% |
| YTD | -94.60% |
| 1Y | -97.66% |
| 52-wk range | $1.71 – $98.75 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for GNPX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.06 – $2.26 |
| Open | $2.26 |
| Prev close | $2.21 |
| Volume | 11.53K |
| Market cap | $1.7M |
| Shares out | 819.71K |

## Valuation and profitability ratios

Valuation and profitability ratios for Genprex, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.12 |
| P/FCF | — |
| ROE | -111.5% |
| ROA | -96.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[Genprex, Inc. Common Stock (GNPX) insider trading](https://massive.com/quote/gnpx/insider-trading.md): open-market Form 4 buys and sells by Genprex, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Genprex, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · Partnership or collaboration
  “In collaboration with and pursuant to a sponsored research agreement with Meharry Medical College in Nashville, Tennessee, Genprex has been exploring aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.”
- Oct 28, 2026 · Partnership or collaboration
  “Genprex established a sponsored research collaboration with Meharry Medical College (Nashville, Tennessee) in 2024 to investigate aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.”
- Aug 18, 2026 · Partnership or collaboration
  “Genprex, Inc. issued a press release announcing it had entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization ("CDMO") to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transition of the Company's therapeutic candidate from research-grade production to clinical and commercial-ready output.”
- Aug 5, 2026 · [Listing compliance regained](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement. The Panel further informed the Company that until December 7, 2026, which represents the full extent of the Panel's discretion in this matter with respect to the Bid Price Requirement, the Company must maintain a closing bid price at or above $1.00 for each trading day.”
- Aug 3, 2026 · Partnership or collaboration
  “Genprex, Inc. issued a press release announcing its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer ('NSCLC'). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.”

## Dividend history and stock splits

Genprex, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-22 · Jul 16, 2026
- 1-for-50 · Oct 21, 2025
- 1-for-40 · Feb 2, 2024

## GNPX short interest

How heavily GNPX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.0 |
| Short interest | 123.26K |
| Avg volume | 170.47K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## GNPX news

The latest news and headlines about Genprex, Inc. Common Stock (GNPX).

- [Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying](https://www.benzinga.com/news/politics/26/02/50874793/congressman-who-bought-small-cap-stocks-in-2025-is-back-with-new-2026-pick-heres-what-hes-buying?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Feb 25, 2026 · neutral sentiment
- [Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics](https://www.benzinga.com/pressreleases/24/09/n40773728/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-t) · Benzinga · Sep 9, 2024 · positive sentiment
- [Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up](https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up) · Zacks Investment Research · Apr 4, 2024
- [Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session](https://www.benzinga.com/news/24/03/37517720/why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-m) · Benzinga · Mar 6, 2024
- [Dow Turns Lower; Federal Reserve Keeps Rates Unchanged](https://www.benzinga.com/news/earnings/24/01/36874214/dow-turns-lower-fed-keeps-rates-unchanged) · Benzinga · Jan 31, 2024

## About Genprex, Inc. Common Stock

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Listed | Mar 29, 2018 |

[Company website](https://www.genprex.com)

## FAQ

### What is the Genprex, Inc. Common Stock (GNPX) stock price today?

Genprex, Inc. Common Stock (GNPX) is trading at $2.08 (-5.88% on the day) as of 7:13:33 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Genprex, Inc. Common Stock?

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and…

### What is the short interest in GNPX?

As of Oct 30, 2026, GNPX has 123.26K shares short and 1.0 days to cover.

### What exchange is GNPX listed on?

Genprex, Inc. Common Stock (GNPX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time GNPX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=GNPX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Genprex, Inc. Common Stock (GNPX) insider trading](https://massive.com/quote/gnpx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
